MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciae603

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study.

Vena Antonio, Tiseo Giusy, Falcone Marco, Bartalucci Claudia, Marelli Cristina, Cesaretti Mario, Di Pilato Vincenzo, Escribano Pilar, Forniti Arianna, Giacobbe Daniele Roberto, Guinea Jesus, Limongelli Alessandro, Lupetti Antonella, Machado Marina, Mikulska Malgorzata, Salmanton-García Jon, Soriano-Martin Ana, Taramasso Lucia, Valerio Maricela, Bouza Emilio, Muñoz Patricia, Bassetti Matteo

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

This study assesses the impact of fluconazole resistance on 30-day all-cause mortality and 1-year recurrence in patients with Candida parapsilosis bloodstream infections (BSI).

METHODS

A multicenter retrospective study was performed at 3 hospitals in Italy and Spain between 2018 and 2022. Adult patients with positive blood cultures for C. parapsilosis who received appropriate targeted therapy with either echinocandins or fluconazole were included.

RESULTS

Among 457 patients, 196 (42.9%) had fluconazole-resistant C. parapsilosis (FLZR-CP) BSI and 261 (57.1%) had fluconazole-susceptible C. parapsilosis (FLZS-CP) BSI. All FLZR-CP patients received targeted echinocandins, while FLZS-CP patients received either echinocandins (60.5%) or fluconazole (39.5%). Unadjusted 30-day all-cause mortality rates were 28.6% for FLZR-CP and 28.4% for FLZS-CP (log-rank test, P = .998). In multivariable analysis, increased mortality was associated with age (adjusted hazard ratio [aHR] 1.03 per year; 95% confidence interval [CI], 1.01-1.05; P = .0005), solid tumor (aHR 1.91; 95% CI, 1.06-3.46; P = .0302), previous antifungal treatment (aHR 1.84; 95% CI, 1.12-3.10; P = .0192), and septic shock (aHR 2.39; 95% CI, 1.42-4.06; P = .0010), but not fluconazole resistance (aHR 1.00; 95% CI, .62-1.63; P = .9864) nor the type of initial antifungal therapy (aHR 1.46; 95% CI, .69-3.06; P = .3202). Propensity score-matched analysis showed no 30-day all-cause mortality difference between echinocandin-treated FLZR-CP and fluconazole-treated FLZS-CP patients (HR 0.81; 95% CI, .37-1.75; P = .5915). However, a higher 1-year recurrence risk was observed in FLZR-CP patients (odds ratio, 7.37; 95% CI, 2.11-25.80; P = .0018).

CONCLUSIONS

Our results suggest that fluconazole resistance is not associated with a higher mortality risk in patients with C. parapsilosis BSI, though 1-year recurrence rates were higher in the FLZR-CP group.

Для цитирования: Vena Antonio, Tiseo Giusy, Falcone Marco, Bartalucci Claudia, Marelli Cristina, Cesaretti Mario, Di Pilato Vincenzo, Escribano Pilar, Forniti Arianna, Giacobbe Daniele Roberto, Guinea Jesus, Limongelli Alessandro, Lupetti Antonella, Machado Marina, Mikulska Malgorzata, Salmanton-García Jon, Soriano-Martin Ana, Taramasso Lucia, Valerio Maricela, Bouza Emilio, Muñoz Patricia, Bassetti Matteo. Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. DOI: 10.1093/cid/ciae603.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.